Why the study?
Dabigatran etexilate was approved to reduce stroke and blood clot risk in nonvalvular atrial fibrillation, with clinical trials comparing it to warfarin.
Does dabigatran reduce stroke and blood clots in patients with nonvalvular atrial fibrillation compared to warfarin?
Does dabigatran reduce stroke and blood clots in patients with nonvalvular atrial fibrillation compared to warfarin?
Answers are grounded in this paper and cite their sources.
Dabigatran is an effective alternative to warfarin for reducing the risk of ischemic and hemorrhagic strokes in patients with nonvalvular atrial fibrillation, though it carries a risk of serious bleeding.
Dabigatran etexilate (Pradaxa) has been approved to lower the risk of stroke and blood clots in patients with nonvalvular atrial fibrillation. In clinical trials, patients taking dabigatran had fewer ischemic and hemorrhagic strokes than patients taking warfarin. As with other anticoagulants, dabigatran may cause serious, even fatal, bleeding.
No takes yet. Share an insight, caveat, or question.
Diane S. Aschenbrenner (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: